Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies

Clinical trial NCT04994626 · UNKNOWN

Trial details

NCT number: NCT04994626
Sponsor: Chinese Academy of Medical Sciences
Status: UNKNOWN
Phase: Phase 2
Study type: INTERVENTIONAL

DLBCL MYD88 Gene Mutation CD79A Gene Mutation CD79B Gene Mutation Relapse Refractory Lymphoma

Start date: 2021-10-01
Primary completion: 2022-04-01
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.